Bárbara Sthefany de Paula Lacerda

Bárbara Sthefany de Paula Lacerda

Auto-generated profile, based on publicly available information

Bárbara Sthefany de Paula Lacerda

Hospital Universitário Cassiano Antonio Moraes, Universidade Federal do Espírito Santo (HU-CAM-UFES)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
JPJessica Polese
Jessica Polese
ARAlessandro Demoner Ramos
Alessandro Demoner Ramos
IMIsac Ribeiro Moulaz
Isac Ribeiro Moulaz
LSLarissa Sant'ANa
Larissa Sant'ANa
BLBárbara Sthefany de Paula Lacerda
Bárbara Sthefany de Paula Lacerda
JMJOSE GERALDO MILL
JOSE GERALDO MILL
The long-term consequences of COVID-19, especially pulmonary impairment, are frequent but not well understood. The knowledge about sequels or long COVID-19 are necessary, considering the high prevalence and need for specific public strategies. The study was conducted to evaluate symptoms (standardized questionnaire), pulmonary function (spirometry), and exercise capacity (6-minute-walk-test) at 30 (D30), 90 (D90), and 180 (D180) days after hospital discharge of patients surviving to severe COVID-19. We excluded in this follow up patients with comorbidities before COVID infection. 44 patients were included and 31 (26 men) completed the 6-month follow-up (age mean 53.6 ± 9.6 years). At D180, 28% presented still at least one symptom. The most common was dyspnea (17.2%), followed by cough (13.8%), and myalgia (10.3%). All spirometric parameters showed progressive improvement from D30 to D180. However, 16% maintained a restrictive pattern on spirometry test, 44% presented desaturation on the 6-minute walk-test, and 25% walked < 75% of the predicted value. 6-months after hospital discharge, reduced pulmonary function and reduced exercise capacity was founded frequently and more than a quarter remained symptomatic. The persistent symptoms and functional impairment suggest that sequels and development of Long COVID-19 are very common. The identification of these patients to provide the necessary health care is a challenging task, considering the large number of patients infected and surviving to COVID-19 disease.

1 January 2025 in Brazilian Journal of Case Reports
Verified
Journal Article
Open access
PDF file
DODanielle Malavazi Oliveira
Danielle Malavazi Oliveira
BLBárbara Sthefany de Paula Lacerda
Bárbara Sthefany de Paula Lacerda
MHMatheus Compart Hemerly
Matheus Compart Hemerly
MSMaria Isabel Lima dos Santos
Maria Isabel Lima dos Santos
WLWeverton Machado Luchi
Weverton Machado Luchi
Xanthogranulomatous pyelonephritis is a rare and aggressive variant of pyelonephritis, characterized by chronic granulomatous inflammation that progresses to destruction of the renal parenchyma and renal failure. Early diagnosis is a challenge. We present the case of a 7-year-old girl with high fever, associated with low back pain, anorexia and vomiting for 30 days. After antibiotic therapy, radical nephrectomy was required for definitive treatment. Due to its rare and aggressive nature, which often leads to the loss of the affected kidney, it is essential to alert healthcare professionals about the importance of early diagnosis to prevent disease progression and improve the patient's prognosis. We will use a case report to explore the clinical, radiological and pathological aspects related to xanthogranulomatous pyelonephritis.

26 April 2023 in Population Medicine
Verified
Journal Article
Open access
GMGabriela de Brito Martins
Gabriela de Brito Martins
BLBarbara Sthefany de Paula Lacerda
Barbara Sthefany de Paula Lacerda
CCCaroline Feitosa Dibai de Castro
Caroline Feitosa Dibai de Castro
MCMarcos Vinicius da Silva Cordeiro
Marcos Vinicius da Silva Cordeiro
MCMargareth Nunes Neves Conceição
Margareth Nunes Neves Conceição
SDStephania Mendes Demarchi
Stephania Mendes Demarchi
Introduction: This study gives insight to work processes in health. It presents letters, chronicles and writings about the activity of community health agents (CHA) who, in their field, have strengths, desires and aspirations. The study was based on Yves Clots clinic of activity and used Michel...

10 February 2022 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
MGMaria da Penha Gomes Gouvea
Maria da Penha Gomes Gouvea
IMIsac Ribeiro Moula
Isac Ribeiro Moula
TGThayná Martins Gouveia
Thayná Martins Gouveia
BTBeatriz Paoli Thompson
Beatriz Paoli Thompson
KLKaren Evelin Monlevade Lança
Karen Evelin Monlevade Lança
VVValeria Valim
Valeria Valim
A pandemia de COVID-19 iniciou a corrida do desenvolvimento de vacinas globalmente. Os trabalhadores da saúde foram o primeiro grupo a receber imunizantes, e no Brasil os mais utilizados foram CoronaVac e AstraZeneca. O presente estudo teve como objetivo avaliar a imunogenicidade e a duração da resposta às vacinas Coronavac e Astrazeneca. Este estudo de coorte foi realizado no Hospital Universitário da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH). No total, 476 trabalhadores da saúde foram recrutados, 261 e 215 foram completamente imunizados com duas doses da vacina CoronaVac (VAC) e AstraZeneca (AZV), respectivamente. Dentre os que receberam o esquema vacinal VAC, a média de idade foi 43 anos. Dentre os que receberam o esquema vacinal AZV, a média de idade foi 44 anos. Os participantes foram acompanhados por meio de coletas de sangue para dosagem dos níveis de anticorpos IgG e IgG anti-spike (IgG-S), no dia da primeira dose (D0), 28 dias após a primeira dose (D28), 28 dias após a segunda dose (D28*) e 180 dias após a primeira dose (D180). Antes da vacinação, 17,5% foram reagentes ao IgG e 42,8% ao IgG-S no grupo VAC (n = 257) e 13,2% para IgG e 29,7% IgG-S foram reativos no AZV. Em ambos os grupos, os níveis de anticorpos foram crescentes com pico 28 dias após a segunda dose com taxa de soroconversão de 100% e queda dos títulos após 180 dias. Após 180 dias, 92,9% se mantivessem reativos no grupo VAC e 100% no AZV no seguimento de 6 meses. No grupo VAC o pico de IgG total foi de 2,17mEq/dL e IgG-S de 1700 AU/mL. Em relação ao grupo de AstraZeneca o pico foi 5617, ± 6101,8 AU/mL. A reatividade humoral induzida pelas vacinas AstraZeneca e CoronaVac foi alta, com taxa de soroconversão de 100% com os dois imunizantes após a segunda dose. A CoronaVac induziu menores títulos de IgG-S, bem como redução de reatividade após 6 meses. Embora não esteja bem estabelecido correlatos de proteção, os títulos mais baixos e queda mais rápida dos níveis de anticorpos específicos, indica necessidade de reforço ou terceira dose. HUCAM-UFES, EBSERH, ICEPi/SESA.

1 January 2022 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
MGMaria da Penha Gomes Gouvea
Maria da Penha Gomes Gouvea
IMIsac Ribeiro Moulaz
Isac Ribeiro Moulaz
TGThayná Martins Gouveia
Thayná Martins Gouveia
KLKaren Evelin Monlevade Lança
Karen Evelin Monlevade Lança
BLBárbara Sthefany de Paula Lacerda
Bárbara Sthefany de Paula Lacerda
VVValeria Valim
Valeria Valim
This study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. The serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucleocapsid (anti-N) IgM and IgG for SARS-CoV-2 was evaluated. IgG antibodies to the SARS-CoV-2 spike receptor-binding domain were used to confirm non-seroconversion in all negative anti-N. Four recurrent cases displayed mild symptoms and were non-seroconverted until the recurrence of symptoms. Undetectable anti-nucleocapsid IgM and IgG levels may be correlated with symptomatic COVID-19 recurrence.